

VII. Agency Contacts

For general questions about this announcement, contact: Technical Information Management Section, CDC Procurement and Grants Office, 2920 Brandywine Road, Atlanta, GA 30341, Telephone: 770-488-2700.

For scientific/research issues, contact: Dr. Mary Lerchen, Extramural Program Official, CDC, National Center for Infectious Diseases, 1600 Clifton Road, NE., Mailstop: C-19, Atlanta, GA 30333, Telephone: 404-639-0043, E-mail: mderchen@cdc.gov.

For questions about peer review, contact: Barbara Stewart, CDC, National Center for Infectious Diseases, 1600 Clifton Road, NE., Mailstop: C-19, Atlanta, GA 30333, Telephone: 404-639-0044, E-mail: bstewart@cdc.gov.

For financial, grants management, or budget assistance, contact:

Sharon Robertson, Grants Management Specialist, CDC Procurement and Grants Office, 2920 Brandywine Road, Atlanta, GA 30341, Telephone: 770-488-2748, E-mail: sqr2@cdc.gov.

VIII. Other Information

None.

William P. Nichols,

Acting Director, Procurement and Grants Office, Centers for Disease Control and Prevention.

[FR Doc. 04-10535 Filed 5-7-04; 8:45 am]

BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES**Centers for Disease Control and Prevention**

[Program Announcement 04173]

Epidemiological Follow-Up of Thyroid Disease in Persons Exposed to Radioactive Fallout From Atomic Weapons Testing at the Nevada Test Site; Notice of Intent To Fund Single Eligibility Award

A. Purpose

The Centers for Disease Control and Prevention (CDC) announces the intent to fund fiscal year (FY) 2004 funds for a grant program to study the prevalence of thyroid disorders and cancers in adults, who, as children, were exposed to radioactive fallout from the nuclear device testing at the Nevada Test Site, 1944-1957. The study is designed to provide a third (Phase III) diagnostic examination of the thyroid gland (approximately 55 years post exposure). The Catalog of Federal Domestic

Assistance number for this program is 93.283.

B. Eligible Applicant

Assistance will be provided only to The University of Utah, Salt Lake City, Utah. The University of Utah, under a previous five-year cooperative agreement and a one-year continuation, initiated data collection activities. They are prepared to initiate activities for Phase III of the Utah Thyroid Disease Study. To date the University of Utah has completed:

1. Developing training materials for the field team.
2. Hired the first of three field teams to perform medical exams.
3. Identified physicians need to perform biopsies of the thyroid gland.
4. Updated the exposure (dose) model algorithm.
5. Revised exposures estimated during Phase II.
6. Completed the identification of subjects needed for the mortality study.
7. Begun to locate and identify the study cohort.

It is in the best interest of the CDC to continue funding the University of Utah to completion of the Utah Thyroid Disease Study.

C. Funding

Approximately \$500,000 is available in FY 2004 to fund this award. It is expected that the award will begin on or before September 1, 2004, and will be made for a 12-month budget period and 12-month project period. Funding estimates may change.

D. Where to Obtain Additional Information

For general comments or questions about this announcement, contact: Technical Information Management, CDC Procurement and Grants Office, 2920 Brandywine Road, Atlanta, GA 30341-4146, Telephone: 770-488-2700.

For technical questions about this program, contact: Robert C. Whitcomb, Jr., Ph.D., Extramural Project Officer, 1600 Clifton Road NE, Mail Stop E-39, Atlanta, GA 30333, Telephone: 404-498-1800, E-mail: Rwhitcomb@cdc.gov.

Dated: May 3, 2004.

William P. Nichols,

Acting Director, Procurement and Grants Office, Centers for Disease Control and Prevention.

[FR Doc. 04-10536 Filed 5-7-04; 8:45 am]

BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES**Centers for Disease Control and Prevention**

[Program Announcement 04181]

Prevention of Mother to Child Transmission of HIV and Improving Access to Comprehensive HIV/AIDS Care for Mother, Family Members, and Other Patients in the Republic of Namibia; Notice of Intent To Fund Single Eligibility Award

A. Purpose

The Centers for Disease Control and Prevention (CDC) announces the intent to fund fiscal year (FY) 2004 funds for a cooperative agreement program to support the infrastructure in Namibia to increase their capacity to prevent HIV transmission from mother-to-child and to improve access to comprehensive HIV/AIDS care and support programs in the public sector. The Catalog of Federal Domestic Assistance number for this program is 93.941.

B. Eligible Applicant

Assistance will be provided only to the Ministry of Health and Social Services (MoHSS) of Namibia for support of the PMTCT and HIV/AIDS care services. No other applications are solicited. In Namibia this program will be implemented under the name "Prevention of mother to child transmission of HIV and improving access to comprehensive HIV/AIDS care for mothers, family members, and other patients in the Republic of Namibia". The MoHSS is the only appropriate and qualified organization to fulfill the requirements set forth in this announcement because:

The MoHSS is uniquely positioned, in terms of support from the Government of Republic of Namibia (GRN). The MoHSS has the ability to financially and technically oversee the project, and to provide implementation of a large-scale interpersonal communication project as well as a mandate from the GRN.

The GRN has mandated the MoHSS to implement nationwide coverage of PMTCT and HIV/AIDS care programs. The vast majority of such patients are under the care of the MoHSS. For example, 84% of the deliveries to HIV-positive women take place in government hospitals compared with 16% in mission hospitals. The MoHSS has the ability to collect information, train staff and advocate for the programs implemented in the National AIDS Strategic Plan and disseminate personalized communication to support

the fight against HIV/AIDS in the Republic of Namibia.

The GRN assisted by the CDC Global AIDS Program conducted a mid-term evaluation of the performance of the national HIV/AIDS program activities in 2003. The results led the GRN to fund the MoHSS to expand efforts to address HIV/AIDS, including PMTCT and ART programs. However, funding for these vital services remains limited. Therefore, MoHSS is the only available organization approved by the GRN to implement PMTCT and comprehensive HIV/AIDS care in the public sector health facilities.

The specific services which the CDC-GAP/MOHSS project will deliver are directly associated with the CDC prevention and care strategies implemented under the Global AIDS Program in the Republic of Namibia and integrated into the MoHSS project. [INSERT JUSTIFICATION STATEMENT FOR SINGLE ELIGIBILITY. IF THE AWARD IS LEGISLATIVELY MANDATED, PLEASE CITE LEGISLATION.]

C. Funding

Approximately \$5,000,000 is available in FY 2004 to fund this award. It is expected that the award will begin on or before May 1, 2004, and will be made for a 12-month budget period within a project period of up to 3 years. Funding estimates may change.

D. Where to Obtain Additional Information

For general comments or questions about this announcement, contact: Technical Information Management, CDC Procurement and Grants Office, 2920 Brandywine Road, Atlanta, GA 30341-4146, Telephone: 770-488-2700.

For technical questions about this program, contact: Dr. Tom Kenyon, Global AIDS Program, c/o U.S. Embassy Windhoek, 2540 Windhoek Place, Washington, DC 20521, Telephone: 264 61 203 2271, Fax number: 264 61 226 959, E-mail: Tkenyon@cdc.gov.

For budget assistance, contact: Shirley Wynn, Grants Management Specialist, CDC Procurement and Grants Office, 2920 Brandywine Road, Atlanta, GA 30341, Telephone: 770-488-1515, E-mail: zbx6@cdc.gov.

Dated: May 3, 2004.

William P. Nichols,

Acting Director, Procurement and Grants Office, Centers for Disease Control and Prevention.

[FR Doc. 04-10532 Filed 5-7-04; 8:45 am]

BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Anti-Infective Drugs Advisory Committee Meeting; Cancellation

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is canceling the meeting of the Anti-Infective Drugs Advisory Committee scheduled for May 10, 2004. This meeting was announced in the **Federal Register** of April 19, 2004 (69 FR 20940).

FOR FURTHER INFORMATION CONTACT: Tara P. Turner, Center for Drug Evaluation and Research (HFD-21), Food and Drug Administration, 5600 Fishers Lane (for express delivery, 5630 Fishers Lane, rm. 1093), Rockville, MD 20857, 301-827-7001, fax: 301-827-6776, or e-mail: TurnerT@cder.fda.gov, or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), code 3014512530.

Dated: April 4, 2004.

Peter J. Pitts,

Associate Commissioner for External Relations.

[FR Doc. 04-10499 Filed 5-7-04; 8:45 am]

BILLING CODE 4160-01-S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Food Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public.

Name of Committees: Food Advisory Committee, Dietary Supplements Subcommittee of the Food Advisory Committee and Contaminants and Natural Toxicants Subcommittee of the Food Advisory Committee. The Food Advisory Committee and its Dietary Supplements subcommittee will meet for the first portion of the meeting; the Food Advisory Committee and its Contaminants and Natural Toxicants subcommittee will meet for the second portion of the meeting.

General Function of the Committees: To provide advice and recommendations to the agency on FDA's regulatory issues.

Date and Time: This meeting will have two parts. The first portion of the meeting will be the Food Advisory Committee and its Dietary Supplements Subcommittee and will be held on June 7, 2004, from 8 a.m. until 5 p.m.; and on June 8, 2004, from 8 a.m. until 1:45 p.m.

The second portion of the meeting will be the Food Advisory Committee and its Contaminants and Natural Toxicants Subcommittee and will be held on June 8, 2004, from 2 p.m. until 6 p.m.

Location: Bethesda Marriott, Grand Ballroom, 5150 Pooks Hill Rd., Bethesda, MD.

Contact Person: Linda L. Reed, Center for Food Safety and Applied Nutrition (HFS-006), Food and Drug Administration, 5100 Paint Branch Pkwy., College Park, MD, 301-436-2397, or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), code 3014510564. Please call the Information Line for up-to-date information on this meeting.

Agenda: FDA has received health claim petitions concerning the following topics: (1) Glucosamine and chondroitin sulfate and osteoarthritis, and (2) crystalline glucosamine sulfate and osteoarthritis. The purpose of the portion of the meeting of the Food Advisory Committee and its Dietary Supplements Subcommittee is to gather information and to receive advice and recommendations relating to the etiology of osteoarthritis, its modifiable risk factors, and the relevance of scientific studies cited in the petitions to substantiating the substance-disease relationship.

The purpose of the portion of the meeting of the Food Advisory Committee and its Contaminants and Natural Toxicants Subcommittee is to discuss data needs pertaining to the evaluation of furan, a chemical formed during thermal treatments of food. Elsewhere in this issue of the **Federal Register**, FDA is publishing a notice that requests the submission of data and information pertaining to the occurrence of furan in food, its mechanism of formation as well as its mechanism of toxicity.

Procedure: Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by May 24, 2004.